Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?

References

• Baber U, Auguste U. Patients with chronic kidney disease/diabetes mellitus: the high-risk profile in acute coronary syndrome. Curr Cardiol Rep. 2013;15:386.
   PubMedGoogle Scholar
• Narala KR, Hassan S, LaLonde TA, et al. Management of coronary atherosclerosis and acute coronary syndromes in patients with chronic kidney disease. Curr Probl Cardiol. 2013;38:165–206.
   PubMed Web of Science ®Google Scholar
• Breet NJ, De Jong C, Bos WJ, et al. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. Thromb Haemost. 2014;112:1174–1181.
   PubMed Web of Science ®Google Scholar
• Htun P, Kan T, Mueller E, et al. Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end stage renal disease. Results of a pilot study. Thromb Haemost. 2014;111:662–669.
   PubMed Web of Science ®Google Scholar
• Tentzeris I, Siller-Matula J, Farhan S, et al. Platelet function variability and non-genetic causes. Thromb Haemost. 2011;105(Suppl 1):S60–6.
   PubMed Web of Science ®Google Scholar
• Jain N, Hedayati SS, Sarode R, et al. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence? Clin J Am Soc Nephrol. 2013;8:665–674.
   PubMed Web of Science ®Google Scholar
• Gabrielli A, Bouatou Y, Saudan P. Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?. Rev Med Suisse. 2014;10:487–490.
   PubMedGoogle Scholar
• Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2013;2:CD008834.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Müller M, Steiner S, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant. 2013;28:2116–2122.
   PubMed Web of Science ®Google Scholar
• Park SH, Kim W, Park CS, et al. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104:1292–1295.
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996;348:1329–1339.
   PubMed Web of Science ®Google Scholar
• CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med. 2001;345:494–502.
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607–1621.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–1189.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717.
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, et al. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420.
   PubMed Web of Science ®Google Scholar
• Keltai M, Tonelli M, Mann JF, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil. 2007;14:312–318.
   PubMed Web of Science ®Google Scholar
• Best PJ, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the clopidogrel for the reduction of events during observation (CREDO) trial. Am Heart J. 2008;155:687–693.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Michael Gibson C, et al. Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. J Thromb Thrombolys. 2011;31:493–500.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015.
   PubMed Web of Science ®Google Scholar
• Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297–1309.
   PubMed Web of Science ®Google Scholar
• Wrishko RE, Ernest CS 2nd, Small DS, et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009;49:984–998.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Briefing document, February 3, 2009 meeting of FDA Cardiovascular and Renal Drugs Advisory Committee on Prasugrel. [ cited 2015 Jan 16]. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm181185.pdf
   Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;61:1045–1057.
   Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800.
   PubMed Web of Science ®Google Scholar
• Serebruany VL. Ticagrelor shift from PLATO to PEGASUS: vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events. Int J Cardiol. 2015;201:508–512.
   PubMedGoogle Scholar
• James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122:1056–1067.
   PubMed Web of Science ®Google Scholar
• Akerblom A, Wallentin L, Siegbahn A, et al. Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients – results from the PLATelet inhibition and patient outcomes (PLATO) study. Am Heart J. 2012;164:728–734.
   PubMed Web of Science ®Google Scholar
• Åkerblom A, Wallentin L, Larsson A, et al. Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet inhibition and patient outcomes (PLATO) study. Clin Chem. 2013;59:1369–1375.
   PubMed Web of Science ®Google Scholar
• Akerblom A, Eriksson N, Wallentin L, et al. Polymorphism of the cystatin C gene in patients with acute coronary syndromes: results from the PLATelet inhibition and patient outcomes study. Am Heart J. 2014;168:96–102.
   PubMed Web of Science ®Google Scholar
• Akerblom Å, Wallentin L, Siegbahn A, et al. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. Clin Chem. 2012;58:190–199.
   PubMed Web of Science ®Google Scholar
• The FDA ticagrelor review of complete response. Available for download at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000MedR.pdf Assessed January 16, 2015
   Google Scholar
• NDA 294-886. Cross-discipline Team Leader review on Vorapaxar. April 18th, 2014. [ cited 2015 Jan 17]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s000SumR.pdf
   Google Scholar
• Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404–1413.
   PubMed Web of Science ®Google Scholar
• Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20–33.
   PubMed Web of Science ®Google Scholar
• Serebruany VL. Redesigning TRACER after TRITON. Intern J Cardiol. 2015;197:44–47.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Kraft WK, Kumar B, et al. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur J Clin Pharmacol. 2012;68:1049–1056.
   PubMed Web of Science ®Google Scholar
• Chiang FT, Shyu KG, Wu CJ, et al. Predictors of 1-year outcomes in the Taiwan acute coronary syndrome full spectrum registry. J Formos Med Assoc. 2014;113:794–802.
   PubMed Web of Science ®Google Scholar
• Blicher TM, Hommel K, Kristensen SL, et al. Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. J Am Heart Assoc. 2014;3:e001116.
   Web of Science ®Google Scholar
• Jeong KH, Cho JH, Woo JS, et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. Am J Kidney Dis. 2015;S0272-6386:01533–9.
   Google Scholar